Genetic Signatures

Genetic Signatures FCF per Share

The Free Cash Flow per Share of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is -0.04 AUD. In the previous year, Free Cash Flow per Share was -0.06 AUD — a change of -33.15% (higher).

FCF per Share

-0.04AUD

YoY

-33.15%

Last updated:

Free Cash Flow per Share of Genetic Signatures is 2026 -0.04 AUD. Free Cash Flow per Share of Genetic Signatures was 2025 -0.06 AUD. It decreases by -33.15% higher compared to the previous year.

The Genetic Signatures FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2019
-0.03 AUD
Jan 1, 2020
-0.08 AUD
Jan 1, 2021
-0.01 AUD
Jan 1, 2022
0.05 AUD
Jan 1, 2023
-0.14 AUD
Jan 1, 2024
-0.07 AUD
Jan 1, 2025
-0.06 AUD
Jan 1, 2026
-0.04 AUD
The Genetic Signatures FCF per Share history
YEARFCF per ShareYoY
-0.04AUD-33.15%
-0.06AUD-14.00%
-0.07AUD-52.79%
-0.14AUD-408.02%
0.05AUD-989.59%
-0.01AUD-93.42%
-0.08AUD+214.96%
-0.03AUD-37.80%
-0.04AUD+17.60%
-0.03AUD+3.05%
-0.03AUD-27.18%
-0.05AUD+31.09%
-0.04AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Free Cash Flow per Share of Genetic Signatures is -0.04 AUD in 2026.

Free Cash Flow per Share of Genetic Signatures changed from -0.06 AUD to -0.04 AUD, representing a -33.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genetic Signatures

All Key Metrics — Genetic Signatures